Literature DB >> 24305500

Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models.

Jochim Reinert1, Henrik Martens2, Melanie Huettenrauch1, Tekla Kolbow2, Lars Lannfelt3, Martin Ingelsson3, Anders Paetau4, Auli Verkkoniemi-Ahola5, Thomas A Bayer1, Oliver Wirths1.   

Abstract

The pathogenesis of Alzheimer's disease (AD) is believed to be closely dependent on deposits of neurotoxic amyloid-β peptides (Aβ), which become abundantly present throughout the central nervous system in advanced stages of the disease. The different Aβ peptides existing are generated by subsequent cleavage of the amyloid-β protein precursor (AβPP) and may vary in length and differ at their C-terminus. Despite extensive studies on the most prevalent species Aβ40 and Aβ42, Aβ peptides with other C-termini such as Aβ38 have not received much attention. In the present study, we used a highly specific and sensitive antibody against Aβ38 to analyze the distribution of this Aβ species in cases of sporadic and familial AD, as well as in the brains of a series of established transgenic AD mouse models. We found Aβ38 to be present as vascular deposits in the brains of the majority of sporadic AD cases, whereas it is largely absent in non-demented control cases. Aβ38-positive extracellular plaques were virtually limited to familial cases. Interestingly we observed Aβ38-positive plaques not only among familial cases due to AβPP mutations, but also in cases of familial AD caused by presenilin (PSEN) mutations. Furthermore we demonstrate that Aβ38 deposits in the form of extracellular plaques are common in several AD transgenic mouse models carrying either only AβPP, or combinations of AβPP, PSEN1, and tau transgenes.

Entities:  

Keywords:  Aβ$_{38}$; AβPP; amyloid; mutations; presenilin; transgenic mice; vasculature; vessels

Mesh:

Substances:

Year:  2014        PMID: 24305500     DOI: 10.3233/JAD-131373

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  9 in total

1.  Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.

Authors:  Nira Cedres; Daniel Ferreira; Milan Nemy; Alejandra Machado; Joana B Pereira; Sara Shams; Lars-Olof Wahlund; Anna Zettergren; Olga Stepankova; Lenka Vyslouzilova; Maria Eriksdotter; Stefan Teipel; Michel J Grothe; Kaj Blennow; Henrik Zetterberg; Michael Schöll; Silke Kern; Ingmar Skoog; Eric Westman
Journal:  Neurology       Date:  2022-08-02       Impact factor: 11.800

2.  Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.

Authors:  Danielle van Westen; Daniel Lindqvist; Kaj Blennow; Lennart Minthon; Katarina Nägga; Erik Stomrud; Henrik Zetterberg; Oskar Hansson
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

3.  The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

Authors:  Steinunn Thordardottir; Anne Kinhult Ståhlbom; Ove Almkvist; Håkan Thonberg; Maria Eriksdotter; Henrik Zetterberg; Kaj Blennow; Caroline Graff
Journal:  Alzheimers Res Ther       Date:  2017-02-16       Impact factor: 6.982

4.  Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer's disease.

Authors:  Carlo Condello; Thomas Lemmin; Jan Stöhr; Mimi Nick; Yibing Wu; Alison M Maxwell; Joel C Watts; Christoffer D Caro; Abby Oehler; C Dirk Keene; Thomas D Bird; Sjoerd G van Duinen; Lars Lannfelt; Martin Ingelsson; Caroline Graff; Kurt Giles; William F DeGrado; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

5.  The Aβ(1-38) peptide is a negative regulator of the Aβ(1-42) peptide implicated in Alzheimer disease progression.

Authors:  Maa O Quartey; Jennifer N K Nyarko; Jason M Maley; Jocelyn R Barnes; Maria A C Bolanos; Ryan M Heistad; Kaeli J Knudsen; Paul R Pennington; Josef Buttigieg; Carlos E De Carvalho; Scot C Leary; Matthew P Parsons; Darrell D Mousseau
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

6.  Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein-β in patients with subcortical small-vessel disease.

Authors:  Petronella Kettunen; Maria Bjerke; Carl Eckerström; Michael Jonsson; Henrik Zetterberg; Kaj Blennow; Johan Svensson; Anders Wallin
Journal:  Alzheimers Dement (Amst)       Date:  2022-03-25

7.  Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Authors:  Erika Avendaño Guzmán; Yvonne Bouter; Bernhard C Richard; Lars Lannfelt; Martin Ingelsson; Anders Paetau; Auli Verkkoniemi-Ahola; Oliver Wirths; Thomas A Bayer
Journal:  Mol Neurodegener       Date:  2014-04-02       Impact factor: 14.195

8.  Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.

Authors:  Jochim Reinert; Bernhard C Richard; Hans W Klafki; Beate Friedrich; Thomas A Bayer; Jens Wiltfang; Gabor G Kovacs; Martin Ingelsson; Lars Lannfelt; Anders Paetau; Jonas Bergquist; Oliver Wirths
Journal:  Acta Neuropathol Commun       Date:  2016-03-08       Impact factor: 7.801

9.  Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.

Authors:  Saima Hilal; Frank J Wolters; Marcel M Verbeek; Hugo Vanderstichele; M Kamran Ikram; Erik Stoops; M Arfan Ikram; Meike W Vernooij
Journal:  Alzheimers Res Ther       Date:  2018-06-30       Impact factor: 6.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.